US · Healthcare · Biotechnology
EPS came in at 1.79 against a street estimate of 1.70 — a beat of 5.3%.
Analysts rate Krystal Biotech Inc a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $385.00.
CONFIDENT VYJUVEK revenue hit $119.2M (+24% YoY) driven by U.S. strength ($91.6M) and early European launches. Pipeline advancing: two ocular registrational readouts imminent, CF and Haley-Haley moving to 2027 trials, KB707 oncology progressing. Germany pricing negotiations ongoing with Q3 resolution expected. Q2 2026 U.S. drove 77% of Q2 revenue. European launches navigating country-specific access dynamics (GMO classification in France, fragmented care in Germany, prescription renewal burden in Japan). Germany pricing negotiations expected to resolve Q3, releasing accrual headwind. Analysts pressed on German pricing accrual impact and European demand durability; management clarified strong underlying vial/patient growth masking near-term reserve headwinds. NK global enrollment and readout timing questioned; management confirmed year-end enrollment, early 2027 data, and EU site activati…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 14.78% |
| BlackRock Inc | 13.31% |
| venBio Select Advisor LLC | 9.76% |
| Vanguard Portfolio Management, LLC | 4.92% |
| State Street Corp | 4.44% |
| Vanguard Capital Management, LLC | 3.94% |
| Soleus Capital Management, L.P. | 3.17% |
| Capital World Investors | 2.63% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 KRYSTAL BIOTECH, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Product Revenue (6 months): $235.6 million vs. $184.2 million prior year (+28% YoY) | 2026-08-03 |
| Results announced · Q3 2026 KRYSTAL BIOTECH Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 VYJUVEK product revenue: $119.2 million, up 24% versus Q2 2025 ($96.0 million) | 2026-08-03 |
| Company announcement · Q3 2026 KRYSTAL BIOTECH, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this disclosure (Form 8-K is an event-based filing, not | 2026-07-21 |
| Shareholder vote results · Q2 2026 KRYSTAL BIOTECH, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held May 15, 2026 • Company trades as KRYS on Nasdaq Glob | 2026-05-20 |
| Quarterly report · Q1 2026 KRYSTAL BIOTECH, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product Revenue Q1 2026: $116.4 million (vs. $88.2 million Q1 2025) – increase of 32 | 2026-05-04 |
| Current report · Q2 2026 KRYSTAL BIOTECH, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced Q1 2026 financial results on May 4, 2026 • Stock trades on Nasdaq Glob | 2026-05-04 |
| Proxy statement · Q2 2026 KRYSTAL BIOTECH, INC. - PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • CEO Total Compensation: The document does not provide specific numerical | 2026-04-03 |
| Annual report FY2025 KRYSTAL BIOTECH, INC. – 2025 10-K SUMMARY HEADLINE NUMBERS • Market value of common stock held by non-affiliates (as of June 30, 2025): $3.5 billion | 2026-02-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2025 revenue and 2026 expense guidance provided ahead of healthcare conference Krystal Biotech announced preliminary 2025 financial results for its gene therapy product VYJUVEK ahead of the J.P. Morgan Healthcare Conference. Key numbers: VYJUVEK generated $106-107 mill | 2026-01-12 |
| Commercial launch of VYJUVEK in Japan following NHI pricing approval Krystal Biotech announced that its Japanese subsidiary began commercial sales of VYJUVEK (beremagene geperpavec) on October 22, 2025, following approval for Japan's National Health Insurance | 2025-10-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Krystal Biotech Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.